Clinical trials: Cardiac Transplant
Coronary Artery Bypass Graft Surgery, Myocardial Ischemia
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
The purpose of this study is to determine the effect of MC-1 on the combined incidence of cardiovascular death and nonfatal myocardial infarction (MI) up to and including 30 days following coronary artery bypass graft (CABG)…
- Conditions
- Coronary Artery Bypass Graft Surgery, Myocardial Ischemia, Reperfusion Injury
- Trial name
- NCT00402506
- Testing
- (MC-1) Pyridoxal 5'-phosphate
- Where
- 2 sites in United States, Canada
- Volunteers
- 3,000 people
- Sponsor
- Medicure
Thrombocytopenia, Thrombosis
Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)
The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS)…
- Conditions
- Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
- Trial name
- NCT00073580
- Testing
- Angiomax (bivalirudin) anticoagulant
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- The Medicines Company
Coronary Artery Disease
VIOLA Post Market Surveillance Clinical Protocol
The goal of this post marketing surveillance clinical trial is to learn about VIOLA as a proximal seal device in patients undergoing coronary artery grafting (CABG) surgery.
- Trial name
- NCT05914246
- Testing
- VIOLA proximal seal
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Vascular Graft Solutions Ltd.
DiGeorge Anomaly, Complete DiGeorge Anomaly
Phase I/II Thymus Transplantation With Immunosuppression #950
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and…
- Conditions
- DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome
- Trial name
- #950 (NCT00579527)
- Testing
- Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Heart Disease
Multi-center Assessment of Grafts in Coronaries: Long-term Evaluation of the C-Port Device
The Study plan is a post-market prospective, multi-center, open-label registry. The vein graft failure rates for the currently commercialized C-Port devices will be compared to an a priori rate taken from the peer-reviewed…
- Trial name
- NCT01478061
- Testing
- Anastomosis (C-Port® )
- Where
- 7 sites in United States
- Volunteers
- 115 people
- Sponsor
- Cardica, Inc
Reduced Left Ventricular Function Defined as LVEF < 50%, Regional Left Ventricular Wall Motion Abnormalities
DESWT-Pilot Study on the Safety of Myocardial Regeneration by Direct Epicardial Shock Wave Therapy in Combination With Coronary Artery Bypass Grafting
Study purpose: To examine the safety of myocardial regeneration by direct epicardial shock wave therapy in combination with coronary artery bypass grafting.
- Trial name
- DESWT (NCT00741065)
- Testing
- Direct Epicardial Shock Wave Therapy
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Cardiac Regeneration Technologies, LLC
Heart Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant.
- Trial name
- NCT02091414
- Testing
- mycophenolate mofetil (MMF), cyclosporine A (CsA), corticosteroids
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Advanced Heart Failure
Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure
The objective of this clinical investigation is to evaluate the efficacy and the safety of the Carmat Total Artificial Heart for the treatment of refractory advanced heart failure in transplant eligible patients.
- Trial name
- EFICAS (NCT04475393)
- Testing
- Carmat Total Artificial Heart, Standard therapy for heart failure
- Where
- 10 sites in France
- Volunteers
- 104 people
- Sponsor
- Carmat SAS
Tricuspid Regurgitation, Tricuspid Regurgitation Functional
Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)
Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).
- Trial name
- NCT06212193
- Testing
- Trillium™
- Where
- 12 sites in United States, Germany
- Volunteers
- 15 people
- Sponsor
- Innoventric LTD
Heart Failure
BeneMACS Study:HeartMate 2 (HM2)Left Ventricular Assist Device (LVAD) Survival in Non Transplant Patients is Equal/Better Than Results in Medical Literature
Study Purpose The purpose of the BeneMACS Long-Term LVAD Study is to demonstrate that survival in non transplant patients implanted with the HeartMate II LVAD as destination therapy in Belgium and the Netherlands are equivalent…
- Trial name
- BeneMACs (NCT00983190)
- Testing
- Left Ventricular Assist Device (HeartMate II)
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- Abbott Medical Devices
Off Pump Coronary Artery Bypass Surgery
Getinge's Beating Heart Product Family Post-Market Clinical Follow-up (PMCF) Study
This observational study aims to collect data on the performance and safety of Getinge's Beating Heart products used during open-heart coronary artery bypass graft surgery.
- Trial name
- NCT07286890
- Testing
- Vacuum Stabilizer System, Vacuum Positioner System, Blower/Mister
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 200 people
- Sponsor
- Maquet Cardiovascular
Heart Transplantation
Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients
This study will test the safety and efficacy of everolimus on heart transplant recipients. This study is not recruiting in the United States.
- Trial name
- NCT00150046
- Testing
- Everolimus
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 176 people
- Sponsor
- Novartis Pharmaceuticals
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer
Arteriosclerosis of Coronary Artery Bypass Graft
Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
This clinical study has been developed to evaluate the clinical outcomes in patients undergoing coronary artery bypass grafting via Minimally Invasive Coronary Surgery (MICS); a minimally invasive coronary bypass procedure that…
- Trial name
- MICS (NCT01334866)
- Testing
- Minimally invasive coronary artery bypass graft surgery
- Where
- 2 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- Medtronic Cardiovascular
Ventricular Dysfunction, Myocardial Infarction
Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone
The object of this open-labeled, uncontrolled pilot study was to investigate the safety and feasibility of percutaneously transplanting autologous bone marrow (ABM) cells into the myocardium using the helical needle…
- Trial name
- TABMMI (NCT00507468)
- Testing
- Transendocaridal Transplantation of Autologous Bone Marrow
- Where
- 2 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- BioCardia, Inc.
Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS
Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients
This purpose of this extension study of patients being treated with EC-MPS is to assess the long term safety of this medication.
- Trial name
- NCT00238446
- Testing
- EC-MPS
- Sponsor
- Novartis Pharmaceuticals